Decision on IPR: Nov 08, 2018
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
IPR2018-00186
|
12/01/2017
|
06/14/2018
|
Pfizer, Inc.
|
9,296,821
|
Biogen Inc.
|
Terminated
|
On US’821 patent, Celltrion previously filed IPR (IPR2017-01095)
in which Board on Oct 04, 2018 issued final written decision & found claims
1-6 unpatentable.
US 9,296,821 (Biogen Inc;
Exp: Jun 11, 2019) – Non OB
1. A method for treating low grade or follicular
non-Hodgkin's lymphoma (NHL) comprising administering to a patient a
therapeutically effective amount of rituximab during a chemotherapeutic regimen,
wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine,
and prednisone (CVP therapy), wherein the method comprises administering 375
mg/m2 of rituximab, and wherein the method provides a beneficial
synergistic effect in the patient.
2. A method for treating low grade or follicular
non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m2
of C2B8 during a chemotherapeutic regimen consisting of cyclophosphamide,
vincristine, and prednisone (CVP therapy).
3. A method for treating low grade or follicular
non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m2
of a chimeric anti-CD20 antibody during a chemotherapeutic regimen consisting
of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the
chimeric anti-CD20 antibody is produced from nucleic acid encoding a light
chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a
heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2,
and comprises human gamma 1 heavy-chain and kappa light-chain constant region
sequences.
4. A method for treating low grade or follicular
non-Hodgkin's lymphoma (NHL) comprising administering to a patient a
therapeutically effective amount of rituximab during a chemotherapeutic
regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide,
vincristine, and prednisone (CVP therapy), wherein the method comprises
administering 375 mg/m.sup.2 of rituximab once every 3 weeks for 8 doses, and
wherein the method provides a beneficial synergistic effect in the patient.
5. A method for treating low grade or follicular
non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m2
of C2B8 once every 3 weeks for 8 doses during a chemotherapeutic regimen
consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy).
6. A method for treating low grade or follicular
non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m2
of a chimeric anti-CD20 antibody once every 3 weeks for 8 doses during a
chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and
prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced
from nucleic acid encoding a light chain variable region comprising the amino
acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the
amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain
and kappa light-chain constant region sequences.
No comments:
Post a Comment